2. Search Result
Search Result
Results for "

CDK4+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103382
    Arcyriaflavin A

    		Fungal Cancer
    Arcyriaflavin A is an indolo[2,3-a]carbazole compound and also a cyclin D1/CDK4 inhibitor. Arcyriaflavin A exists in the marine ascidian Eudistoma sp. and the slime mold Arcyria denudata. Arcyriaflavin A is applicable to research related to colon cancer and lung cancer .
    Arcyriaflavin A
  • HY-164129
    CDK4-IN-3

    		CDK Apoptosis Cancer
    CDK4-IN-3 (Compound 389) is a potent irreversible cyclin-dependent kinase 4 (CDK4) inhibitor (IC50=25 nM, >10-fold selective over CDK6). CDK4-IN-3 arrests the cell cycle at G₁ phase, and induces tumor cell apoptosis. CDK4-IN-3 is promising for research of solid tumors such as breast and lung cancers .
    CDK4-IN-3
  • HY-15612
    CDK4-IN-1

    		CDK Cancer
    CDK4 inhibitor is a novel and specific CDK4/Cyclin D1 inhibitor with an IC50 of 10 nM; 1500 and 500 fold than CDK1/Cyclin B (IC50>15 uM) and CDK2/Cyclin A (IC50=5.265 uM) respectively.
    CDK4-IN-1
  • HY-112243A
    Cimpuciclib tosylate

    		CDK Inflammation/Immunology Cancer
    Cimpuciclib tosylate is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity .
    Cimpuciclib tosylate
  • HY-156646
    Tibremciclib

    		CDK Cancer
    Tibremciclib is a CDK4 inhibitor with antineoplastic activity .
    Tibremciclib
  • HY-103380
    NSC 625987
    1 Publications Verification

    		 CDK Cancer
    NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
    NSC 625987
  • HY-112243
    Cimpuciclib

    		CDK Inflammation/Immunology Cancer
    Cimpuciclib is a selective CDK4 inhibitor (IC50: 0.49 nM) that has anti-tumor activity .
    Cimpuciclib
  • HY-153443
    CDK4-IN-2

    		CDK Cancer
    CDK4-IN-2 (A17) is a CDK4 inhibitor, with Ki and IC50 values of <10 nM. Used in cancer research .
    CDK4-IN-2
  • HY-47733
    CDK1/2/4-IN-2

    		CDK Cancer
    WAY-643018 (Compound 2), an indazolecarboxamide derivative, is a CDK1, CDK2, and CDK4 inhibitor. CDK1/2/4-IN-2 has the potential for cancer research .
    CDK1/2/4-IN-2
  • HY-172127
    NUAK1-IN-1

    		AMPK CDK Neurological Disease Cancer
    NUAK1-IN-1 (Compound 9) is a NUAK1 (IC50 of 5.012 nM) and CDK4 inhibitor. NUAK1-IN-1 can be used in cancer, neurodevelopmental disorders and Alzheimer's disease research .
    NUAK1-IN-1
  • HY-171740
    CDK4-IN-4

    		CDK Cancer
    CDK4-IN-4 (example 30) is a selective CDK4 inhibitor (IC50＜10 nM) that can be used in cancer research .
    CDK4-IN-4
  • HY-103380R
    NSC 625987 (Standard)

    		Reference Standards CDK Cancer
    NSC 625987 (Standard) is the analytical standard of NSC 625987 (HY-103380). This product is intended for research and analytical applications. NSC 625987 is a specific and high-affinity CDK4 inhibitor with an IC50 of 0.2 μM for CDK4:cyclin D1. NSC 625987 shows >500-fold selectivity for CDK4 over CDK2 .
    NSC 625987 (Standard)
  • HY-183297
    CDK4-IN-5

    		CDK Cancer
    CDK4-IN-5 is a potent, orally active and selective CDK4 inhibitor. CDK4-IN-5 suppresses CDK4 expression and downregulates the CDK4/CyclinD1 complex. CDK4-IN-5 induces G0/G1 phase cell cycle arrest in bladder cancer cells via CyclinD1 expression suppression. CDK4-IN-5 selectively exerts activity against bladder cancer cells. CDK4-IN-5 can be used for the research of bladder cancer .
    CDK4-IN-5
  • HY-118447
    RO0505124

    		CDK Survivin Cancer
    RO0505124 is a selective CDK4 inhibitor with an IC50 of 20 nM. RO0505124 reversibly binds the ATP pocket of the kinase. RO0505124 induces G1 phase arrest in cancer cells via reduced retinoblastoma protein (Rb) phosphorylation, blocking S phase progression. RO0505124 exhibits anti-proliferative activity against various cancer cells. RO0505124 delays mitotic entry, induces aberrant mitosis with lagging chromosomes, driving mitotic slippage and formation of multinucleated or micronucleated cells. RO0505124 inhibits G2/M phase accumulation of survivin and borealin. RO0505124 can be used for the research of cancer .
    RO0505124

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: